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Developments in chemotherapeutic strategies and surgical technique have led to improved loco regional control of rectal cancer
and a decrease in recurrence rates over time. However, locally recurrent rectal cancer continues to present considerable technical
challenges and results in signiﬁcant morbidity and mortality. Surgery remains the only therapy with curative potential. Despite
a hostile intra-operative environment, with meticulous pre-operative planning and judicious patient selection, safe surgery is
feasible. The potential beneﬁt of new techniques such as intra-operative radiotherapy and high intensity focussed ultrasonography
hasyettobethoroughlyinvestigated.Thefutureliesinidentiﬁcationofpredictorsofrecurrence,developmentofschematicclinical
algorithms to allow standardised surgical technique and further research into genotyping platforms to allow individualisation of
therapy. This review highlights important aspects of pre-operative planning, intra-operative tips and future strategies, focussing
on a multimodal multidisciplinary approach.
1.Introduction
L o c a lr e c u r r e n c eo fr e c t a lc a n c e ri sd i ﬃcult to treat, may
cause severe disabling symptoms, and often holds a dismal
prognosis. Surgery remains the cornerstone of management
for the majority of primary rectal cancers. Despite a marked
improvement in local control with the popularisation of
Total Mesorectal Excision (TME) and the use of improved
chemoradiotherapeutic regimen, recurrence continues to
present a signiﬁcant clinical problem. Reﬁnements in man-
agement have, however, led to a decrease in locoregional
rectal cancer recurrence rates from 25–40% to 4–8% [1].
Since 20% to 50% of these patients has local recurrence
in the absence of distant metastasis, it is intuitive that
surgical management represents a viable treatment option
[2]. Surgery for locally recurrent rectal cancer, however,
requires the undertaking of complex techniques in a hostile
operative environment and in many cases requires input
from other specialities such as urology, gynaecology and
vascular teams. These surgeries should in principle only be
performed in a tertiary centre with appropriate surgical,
anaesthesiology, and intensive care expertise. Postoperative
morbidity is high, ranging from 15–70% and increases
with the complexity of resection performed [3, 4]. As a
result, surgical management of local recurrence of colorectal
cancer has not attained the international approval which has
been bestowed upon resection of distant metastases such
as hepatic disease. Despite many potential pitfalls, surgery
remains the only therapy with curative potential and safe
surgery is feasible. This paper highlights pertinent issues
regarding surgical preparation and techniques with a focus
on the importance of a multimodal approach.
2. Mode of Presentationand Risk Factors
In 70% of cases, recurrence of rectal cancer occurs within
two years of primary surgery, while 85% occurs within 3
years [4, 5]. Mode of presentation is varied and may be
dependent on the site of disease. Up to one-third of patients
does not present with any symptoms [4, 5], emphasising the
importance of a carefully designed and diligent schedule of
postoperative followup. A recent population-based cohort
study of 57 patients concluded that followup after rectal can-
cer surgery by annual clinical examination is not suﬃcient.
They reported that at diagnosis of local recurrence 86% of2 International Journal of Surgical Oncology
patients was symptomatic and 70% was diagnosed between
scheduled follow-up visits [6]. The nature of this schedule is
dependentonthetypeofprimaryresectionperformed.After
sphincter-preserving surgery, surveillance to facilitate early
diagnosis of recurrence should comprise digital rectal exam-
ination, sigmoidoscopy, and enquiry regarding symptoms of
bleeding or changes in bowel habit. In contrast, the majority
of local recurrences after abdominoperineal resections are
diagnosed after detection of elevated CEA levels or upon
report of pelvic pain [7]. When present, symptoms tend to
be disabling and persistent. Refractory pelvic pain, tenesmus
andmalodorousdischargearecommon[8]andqualityoflife
is often detrimentally aﬀected [9, 10]. Pain on presentation
has been identiﬁed as a signiﬁcant predictor of inferior long-
term survival [11, 12]. This is likely related to the association
b e t w e e ne x t e n to fp a i na n dd e g r e eo fﬁ x a t i o ni nt h ep e l v i s ,
reﬂecting a more advanced stage of local recurrence at
presentation and therefore worse prognosis.
Several risk factors are reported to be associated with
local recurrence. These may be broadly grouped into
pathological, anatomic, and surgical factors. Degree of lym-
phovascular invasion, diﬀerentiation, and tumour size has
been associated with increased risk of local recurrence [13].
Anatomically, positive circumferential or distal resection
margin at initial resection, including positive microscopic
margins, increases risk. In patients who have received
neoadjuvant chemoradiation, a margin of less than 1cm is
considered oncologically adequate [14]. Patients operated
on in high-volume centres have also been reported to
enjoy lower recurrence rates [15] and surgical technique
may also play a role. In selected series, abdominoperineal
resection (APR) has been associated with higher recurrence
rates than sphincter-preserving surgery [16]. In addition,
newer lower excision techniques such as transanal endo-
scopic microsurgery (TEMS) may also increase risk and
patients should be carefully selected since recurrence rates
are increased according to stage. A retrospective analysis of
74 patients with T1 and T2 rectal adenocarcinoma treated
with TEMS and 100 patients with T1N0M0 and T2N0M0
rectal adenocarcinoma treated with radical surgery showed
a statistical diﬀerence in 5-year local recurrence rates for
T2 but not T1 cancers [17]. Elevation in serum CEA lacks
sensitivity (59%) but has a speciﬁcity of 84% [18]. Recent
eﬀorts towards identifying novels biomarkers to predict
recurrence in colorectal cancer have shown early promise
[19]; however, further investigation is necessary.
3. AnatomicalClassiﬁcation
Although TME has contributed dramatically to improved
management of primary rectal cancer, its popularisation
decreases the likelihood that a recurrent neoplasm will
remain conﬁned to a speciﬁc compartment due to the
absence of visceral rectal fascia [20]. Locally recurrent rectal
cancer is generally grouped according to anatomic location.
An alternative system, used at the Mayo Clinic, classiﬁed
these tumours according to the presence of symptoms, with
a particular focus on pain, as well as degree of ﬁxation.
Although the anatomical system may be imperfect, it is
currently the most widely accepted method of classiﬁcation.
Due to the fact that surgical approach is largely dictated by
the location of recurrence and relationship to surrounding
structures, the use of an anatomical classiﬁcation system is
practical in this setting. Axial recurrences are conﬁned to the
pelvic organs without invading into bone or sidewall. This
includes anastomotic recurrence after low anterior resection
(LAR), recurrence after local excision procedures, such as,
TEMS and perineal recurrence after APR [21]. Tumours in
thepresacralspacewhichinvadeintothesacrumaregrouped
as sacral or posterior recurrences. Anterior recurrences may
involve genitourinary organs. Sidewall or lateral recurrence
is diagnosed when tumour invades iliac vessels, pelvic
autonomic nerves, pelvic ureters or extends through the
greater sciatic foramen [22]. A growing body of evidence
showsprognosisvariesaccordingtositeofrecurrence.Moore
et al. reported that lateral or sidewall recurrences were less
likely to be curatively resected than axial or anterior [14].
4.SurgicalManagement:
Preoperative Preparation
Without intervention, prognosis of recurrent rectal cancer is
dismal with median survival typically 6-7 months [8, 23].
These patients endure symptoms which are catastrophic
to quality of life including refractory pain, discharge, and
tenesmus. Only 30% of patients achieve symptom control
with radiotherapy alone and this treatment option rarely
improves survival beyond one year [24]. Radical surgery
oﬀers the only hope of complete therapy and up to 50%
of cases is conﬁned to the pelvis and thereby labelled
theoretically amenable to cure [25]. Additionally, in carefully
selected patients, surgery may be of beneﬁt even in the
presence of distant metastases with metastatsectomy gaining
favour [24]. Morbidity and mortality rates of radical surgery
for recurrences are high and can reach 60% and 8% (at 3
months), respectively [5].
Surgery for recurrent rectal cancer is a challenging un-
dertaking which should ideally be individualized and per-
formed in a specialist unit with early involvement of a mul-
tidisciplinary team. A recent systematic review reported that
the proportion of potentially curative resections has in-
creased in recent years, probably due to improved staging,
neoadjuvant treatment, and increased surgical experience in
dedicated centres, which has resulted in improved survival
[26].Resectionsofthisnature,however,remainvulnerableto
complication and the operative environment is often hostile.
Normal tissue planes are frequently obliterated, tissues may
be friable from previous irradiation, dense adhesions are
often present, and ﬁbrosis may be extensive. Unexpected
discovery of previously undiagnosed peritoneal or visceral
metastases is not uncommon and is a poor prognostic
indicator. As a result, as much information as possible
should be gathered preoperatively and communication with
the patient regarding inherent risks is crucial. A specialist
colorectal nurse should be involved at an early stage as a
link between the patient and the lead clinician. A systematicInternational Journal of Surgical Oncology 3
approach is optimum and some guidance can be found in
the literature. Bouchard and Efron recommend a full blood
panel including carcinoembryonic antigen testing as well as
thorough physical examination [21]. Where necessary this
should be supplemented by digital rectal examination, vagi-
nal examination, sigmoidoscopy, cystoscopy, or examination
under anaesthesia. Full details of previous surgeries should
be sought if not performed in the same centre. Mirnezami et
al. advocate early assembly of a multidisciplinary which may
include orthopaedic, urologic, gynaecologic, and vascular
surgeonsaswellascolorectalspecialists[24].Plasticsurgeons
may also be required as recent technical improvements
in reconstructive options have contributed signiﬁcantly to
outcome and quality of life.
Thorough preoperative staging is crucial to optimum
planning and determination of resectability. Mirnezami et al.
provide an excellent algorithm for initial approach to surgi-
cally resectable recurrent rectal cancer [24]. Computerized
Tomography (CT) can be used to conﬁrm the presence of
a mass and investigate the presence of distant metastases.
If a distant lesion is identiﬁed or if occult tumour or
metastases are suspected, Positron Emission Tomography
(PET) with ﬂuorodeoxyglucose (FDG) may provide useful
information to establish a diagnosis and to assess the
location and metabolic activity. The ability of Magnetic
ResonanceImaging(MRI)todiﬀerentiatesofttissuecontrast
resolution makes it useful in assessing the precise site of
the tumour including relationship to vessels. Both MRI
and CT demonstrate low sensitivity in accurate assessment
of side wall involvement [21]. With MRI the danger of
false-positive readings in patients who have received recent
radiotherapy remains an issue and diﬀerentiation between
ﬁbrosis and malignant tissues is not deﬁnitive. A recent
retrospective study assessing the accuracy of preoperative
magnetic resonance (MR) imaging for identiﬁcation of
tumour invasion into pelvic structures in 40 consecutive
patients found that MRI had a negative predictive value of
93%–100%. Interestingly, assessment failures were mainly
because of misinterpretation of diﬀuse ﬁbrosis, especially at
the pelvic side walls [27]. For this reason, it is crucial to
procuretissueforhistologicalconﬁrmationoftherecurrence
where possible either by colonoscopy-or CT-guided biopsy.
In cases where this is not possible, a detailed and frank
patient discussion is imperative, conveying the high-risk
nature of surgery versus uncertainty regarding the diagnosis.
Ifpatientorsurgeonisreluctanttoproceed,watchfulwaiting
is an alternative course of action [24].
5.SurgicalManagement: Timing,
Contraindications,andResectability
Determination of resectability should not only assess
anatomic feasibility of performing an R0 resection but also
ability to attain an acceptable level of morbidity and mor-
tality. Careful patient selection is crucial and when surgery is
planned,rigorouspreoperativeassessmentofﬁtnessisneces-
sary. High patient comorbidity load often represents the ﬁrst
contraindication to surgery. If physical examination reveals
lowerlimboedema,acauseshouldbesoughtaslymphaticor
venous obstruction represents an absolute contraindication
to surgery. Other anatomic factors identiﬁed in preoperative
imaging,suchas,encasementofiliacvessels,bilateralureteric
obstructionofcircumferentialinvolvementofthepelvicwall.
This is because ability to obtain negative margins is signiﬁ-
cantly compromised by involvement of these structures [14].
Tumourswhichinvolvetheuretersoriliacvesselsmayalsobe
associated with bony involvement at S1 and S2 level. Sacral
invasion above the S2-S3 junction will almost invariably
require the patient to undergo internal ﬁxation due to
sacroiliac instability. Relative and absolute contraindications
are the subject of some controversy in the literature with
manysmallstudiesreporting conﬂictingresults.Henry et al.,
for example, conducted a retrospective analysis of single-
centre experience and concluded that hydronephrosis should
notconstituteanindependentcontraindicationtoattempted
curative resection [28]. Maslekar et al. also recently reported
resection of recurrence with encasement of external iliac
vessels [29]. With advances in surgical technique it is likely
that in the future more and more contraindications may
move from being categorised as absolute to relative.
If the patient is radiotherapy naive, at our centre, we
administer long-course chemoradiotherapy (40–50Gy) to
improvelocalcontrolandpotentialforcurability.Thetiming
of surgery may then be dictated by a 6–8 week wait after
treatment followed by thorough restaging [30]. It is well
recognised that the normal tissue tolerance of the intestine is
often the dose-limiting factor in the administration of pelvic
and abdominal radiotherapy.
6. SurgicalManagement: GeneralPrinciples
Having completed the extensive preoperative phase, some
general principles apply to operative approach. Aids such as
ureteric stents, radiological tattooing of surface markings for
the level of sacrectomy, and preoperative marking of stoma
site may be helpful [24]. A multimodal strategy has gained
favour in the recent past. If intraoperative radiotherapy
is planned certain infrastructure is required, such as, a
specialised table to enable patient positioning and optimum
delivery. Generally, the patient is ﬁrst put in the Lloyd-
Davies position but may need to be moved to the prone
position if sacral resection is planned. Exposure is critical
and in our practice we generally make an incision from the
xiphisternum to symphysis pubis. Wound protectors may be
used to reduce potential for infection and deposit of tumour
cells in the wound. Many surgeons favour a Bookwalter
retractor for exposure. Complete mobilization of the small
intestine is advised to rule out the presence of metastases.
This phase may be time consuming due to the potential
requirement for extensive adhesiolysis and the small bowel
is often adherent within the pelvis. If a small bowel segment
is adherent to the pelvic malignancy then it must be removed
en-bloc. If ascitic ﬂuid is present a sample is sent for
cytology. In commencing pelvic dissection, Bouchard and
Efron recommend beginning in a plane free of adhesions
in an area away from the tumour where possible [21].4 International Journal of Surgical Oncology
Intraoperatively, as with imaging, diﬃculties may arise in
accurately distinguishing tumour from radiotherapy-related
ﬁbrosis. This conﬂict limits the use of less radical approaches
signiﬁcantly. There may a role for the use of frozen section
intraoperatively if this helps in the decision to proceed to a
more aggressive dissection versus conservative management.
In many cases it may take several hours of exploration of the
various planes before one can be conﬁdent that resection is
feasible.
The decision regarding how to proceed with central or
axial recurrences is heavily related to the involvement of
urogenital organs and the primary procedure previously
performed. In the case of involvement of urogenital organs,
curative resection requires an en-bloc-extended radical
approach according to the patient’s gender. If the dome
of the bladder alone is involved, a partial cystectomy will
generally suﬃce. If the trigone is involved, and the prostate
inmales,totalpelvicexenterationanden-blocprostatectomy
are the only curative option. In addition to MRI, cystoscopy
performed prior to deﬁnitive surgery will help with surgical
planning and patient consent, according to area of bladder
involved. In females, involvement of the uterus or vagina
requires hysterectomy. Reconstructive options, such as, an
ileal conduit, colonic conduit, or vaginal reconstruction
are possible. In the absence of urogenital involvement,
the patient’s primary procedure dictates management. In a
patient who has undergone a previous anterior resection,
Mirnezami and Sagar recommend radical resection outside
the original plane of dissection [22]. If the primary surgery
was an abdominoperineal resection (APR), a pelvic recur-
rence can be treated with resection of the mass and involved
small bowel where necessary. With perineal recurrence, a
transperineal approach may be possible and a posterior
distal sacrectomy may be required. In the case of previous
APR, the empty pelvis often contains involved loops of
small bowel which must be resected en-bloc with the mass.
The ensuing perineal defect will generally require a rectus
abdominus or gracilis ﬂap. There is currently no guidance
in the literature regarding the extent of lymphadenectomy
required and equipoise on this issue cannot be reached in the
absence of a further clinical trials.
Presacral venous haemorrhage may be extensive, diﬃ-
cult to control with conventional haemostatic agents and
potentially life threatening. Before embarking on a resection
in this area, provisions should be made for the potential
requirement of blood products, aggressive ﬂuid resuscita-
tion, synthetic haemostatic agents, and devices, such as,
thumbtacks [31]. Sacral recurrence is best managed via two-
stage-combined abdominosacral approach [22]. Dissection
in the presacral plane is necessary until the mass is reached.
If neural and vascular involvement is absent, limited, or
conﬁrmed to be compatible with resectability, the patient
maybemovedtotheproneposition,allowinggoodexposure
If the tumour invades the sacrum at the S1 or S2 level we
would deem this unresectable. Some centres may consider
resection with subsequent internal ﬁxation, but we believe
that ensuing deterioration in quality of life could not justify
the risk to beneﬁt ratio. If the tumour is distal to S2 then a
distal sacrectomy may be performed with en-bloc resection
of the previously formed neorectum or mass. Stomas and
ileal conduits are constructed and omentoplasty may be
undertaken to ﬁll the pelvis. This reduces the potential for
small bowel to become adherent to the raw pelvic surface
causing obstruction and reduces the potential for perineal
wound breakdown. The more extensive the sacrectomy
performed, the worse are the morbidity, mortality, and
quality of life. After less extensive sacral amputation, some
series report a more acceptable quality of life despite stomas
and temporary pain owing to the resection of sacral nerves
[32]. A recent small series from the Mayo Clinic reported
promising results from high sacrectomy indicating that these
surgeries may be safely performed in centres of excellence
[33]. Despite a median operative time of 13.7 hours and
median operative blood transfusion of 3.7 litres, thirty-day
mortalitywasnil.Theoverallmediansurvivalwas31months
(range 2–39 months), and all deaths were due to metastatic
disease. Although only nine patients were included in this
study, similar reports are emerging from other centres [34]
and potentially indicate that high sacrectomy that achieves
clear margins in patients with recurrent rectal cancer is
feasible. Primary closure of the skin and fat is vulnerable
to wound complications, and therefore a myocutaneous ﬂap
using the rectus abdominus or the gluteal muscles may be
employed [26, 35].
The group associated with worst prognosis and resec-
tabilitypotentialisthegroupinvolvingthelateralpelvicside-
wall [20]. A recent review reported that the more widespread
use of TME has increased the incidence of pelvic sidewall
recurrence [26]. Extensive involvement is a relative con-
traindication to operative intervention as key structures such
as the ureters, iliac vessels, and sciatic nerve may be involved.
Resection of the iliac vessels is associated with signiﬁcant
bleeding and as discussed, preoperative stenting of the
ureters is advisable to facilitate dissection and identiﬁcation
of the ureters during the ﬁrst phase of the surgery which
should begin at the pelvic brim [36]. Early control of vessels
and other key structures such as the obturator nerve, is
imperative to success and progression to extended radical
resection is usually required [24].
7. Palliation for RecurrentRectal Cancer
In patients not ﬁt for surgical intervention or with disease
deemed unresectable, radiotherapy may play a role [37].
It is very eﬀective in the treatment of pelvic pain and
ongoing bleeding. The use of external beam radiotherapy
has been reported to control pelvic pain in over 90%
of cases and thus provide improved quality of life for
aﬀected patients. In patients with impending obstruction
the use of self-expanding metal stents (SEMSs) is eﬀective
[38]. If the tumour is very low or the stent fails then
a laparoscopic defunctioning stoma may be required to
alleviate impending instruction. In patients with bilateral
hydronephrosis ureteric stents either retrograde or antegrade
will relieve the obstruction and prevent renal failure. If the
ureters are completely obstructed then nephrostomy tubes
are required.International Journal of Surgical Oncology 5
8.SurgicalManagement: Multimodal Approach
While it is widely agreed that multimodal therapy is the
future of management of recurrent rectal cancer, the use of
Intraoperative Radiotherapy (IORT) remains controversial.
IORT may be advantageous when bony involvement pre-
cludes the possibility of R0 resection [5]. Indeed, several
studies have demonstrated a beneﬁt in survival with IORT,
particularlyincombinationwithpreoperativechemotherapy
[12,39].IORThasbeenshowntoresultinsigniﬁcantlybetter
three-year survival, disease-free survival, and local control in
IORT-multimodal groups compared with historical control
groups [40]. The overall survival after multimodal therapy
at 5 years is approximately 30% at present [41]a n dw h e n
IORT is used as a component of this treatment, an increased
survival rate of 15% can be demonstrated [39, 42].
9. The Future
Given the relatively poor prognosis despite multimodal
treatment, the future of recurrent rectal cancer manage-
ment lies in scientiﬁc progress, optimised technique, new
treatments, and carefully designed clinical trials. The ﬁrst
case of transrectal high-intensity focused ultrasonography
as a therapeutic option for advanced recurrent rectal can-
cer has recently been reported [43]. Potentially promising
ongoing work includes identiﬁcation of novel biomarkers as
predictors of recurrence [19], discovery of novel alleles for
use in targeted screening and personalized prevention [44–
46], and development of systematic clinical algorithms [24].
Individualization of therapy in the future may be possible
with next-generation genotyping platforms [47]. Although
the popularisation of TME has resulted in decreased in-
cidence of recurrence in rectal cancer, pelvic sidewall re-
currence has increased, and tumours are less likely to be con-
tained within deﬁned compartments. Advances in imaging
modalities and technical progress, however, have facilitated
better selection of candidates for resection and substantially
improved outcome as a result. Strategies for early detection
require improvement and surgical techniques should be
standardised. At present, best practice should include metic-
ulous preoperative planning and adoption of a multimodal
approach in centres of excellence with early involvement of
a multidisciplinary team. A considerable amount of time
must be spent counselling the patient and their family to
facilitate thorough understanding of inherent risks and to
ensure realistic expectations.
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